Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: veratx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/25/2024 | $26.00 | Outperform | Oppenheimer |
1/8/2024 | Overweight | Cantor Fitzgerald | |
12/18/2023 | $29.00 | Outperform | Raymond James |
11/10/2023 | $18.00 → $26.00 | Hold → Buy | Jefferies |
8/16/2023 | $27.00 | Buy | Guggenheim |
1/4/2023 | $32.00 → $6.00 | Buy → Hold | Jefferies |
1/4/2023 | $33.00 → $8.00 | Outperform → Neutral | Wedbush |
7/12/2022 | $35.00 | Overweight | JP Morgan |
5/2/2022 | $35.00 | Buy | H.C. Wainwright |
4/19/2022 | $32.00 | Outperform | Wedbush |
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
3 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
3 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
SC 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)
BRISBANE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host an in-person and virtual R&D Day in New York, NY at 8:00 AM ET on Wednesday, October 2, 2024. To register, click here. The event will feature Jonathan Barratt, MD, PhD, FRCP (University of Leicester), Richard Lafayette, MD, FACP (Stanford University Medical Center), and Brad Rovin, MD (Ohio State University Wexner Medical Center), who will join the company's management team to discuss Vera's expanded ataci
On track to announce topline results from ORIGIN 3 trial in Q2 2025Expect to present 96-week data from ORIGIN Phase 2b clinical trial of atacicept in IgAN in Q4 2024 BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed enrollment ahead of schedule for the primary endpoint in the pivotal Phase 3 ORIGIN 3 trial of atacicept in patients with IgAN. The enrollment of 200 participants in this initial cohort of the trial will provide data for the 36-week UPCR
BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on September 5, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 21,750 shares of Class A common stock and restricted stock units (RSUs) for 9,875 shares of Class A common stock to two new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option granted on September 5, 2024 has an exercise price per share equal to $38.16, Vera's closing trading price on September
BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at investor conferences being held in September. Investor Conference Details: Wells Fargo Healthcare ConferenceFormat: 1x1sDate: Thursday, September 5, 2024Location: Boston, MACantor Global Healthcare ConferenceFormat: Fireside Chat and 1x1sWebcast: https://wsw.com/webcast/cantor22/vera/2084634Date: Wednesday, September 18, 2024Time: 9:1
BRISBANE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on August 6, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 33,000 shares of Class A common stock and restricted stock units (RSUs) for 16,500 shares of Class A common stock to three new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option granted on August 6, 2024 has an exercise price per share equal to $37.44, Vera's closing trading price on August 6, 20
Received FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN)Presented data from Phase 2b ORIGIN study at ERA24 Congress showing atacicept stabilized kidney function through 72 weeks and led to rapid reductions in hematuriaTopline 96-week data from Phase 2b ORIGIN study expected in Q4 2024On track to complete enrollment in pivotal Phase 3 ORIGIN 3 trial for primary endpoint in Q3 2024; topline data expected in Q2 2025 BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological
BRISBANE, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on July 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 160,000 shares of Class A common stock to David Johnson, Vera's new Chief Operating Officer, under Vera's 2024 Inducement Plan. Vera also announced that on July 2, 2024, the Compensation Committee granted additional inducement awards consisting of a non-qualified stock option to purchase 139,100 shares of Class A common stock and restricted stock units (RSUs) for 61,925 shares of Class A common stock to ten new employees under th
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, taking place June 10 – 13, 2024 at the Loews Miami Beach Hotel, Miami Beach, FL. Presentation Details: Date: Wednesday, June 12, 2024 Time: 10:40 AM EDTPresenter: Marshall Fordyce, M.D., Chief Executive Officer The management team will also participate in one-on-one investor meetings. About VeraVera Therapeut
10-Q - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
DEFA14A - Vera Therapeutics, Inc. (0001831828) (Filer)
ARS - Vera Therapeutics, Inc. (0001831828) (Filer)
DEFA14A - Vera Therapeutics, Inc. (0001831828) (Filer)
DEF 14A - Vera Therapeutics, Inc. (0001831828) (Filer)
New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la
Vera continuing plans to rapidly advance atacicept into a pivotal Phase 3 trial in 1H 2023; full data to be presented at upcoming medical congresses Company plans to prioritize and focus current resources on the advancement of atacicept in IgA Nephropathy into a pivotal Phase 3 trial, extending cash runway to Q4 2024 Conference call and webcast to take place on January 30th at 8:00am ET BRISBANE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced results from a prespecified per-protocol (PP)
Atacicept met primary endpoint at 24 weeks, and also achieved statistical significance in the 150 mg dose group with a 33% mean reduction in proteinuria from baseline, with available data showing trend towards further reductions in proteinuria at week 36 Atacicept safety profile in IgAN patients was similar to placebo Vera plans to advance atacicept into a pivotal Phase 3 trial in the first half of 2023 Company to host investor conference call and webcast on January 4, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing
BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on March 24, 2022. Title:Vera Therapeutics Business Update Call Date:Thursday, March 24, 2022 Time:8:00 a.m. ET Conference Call Details:Toll-Free: 1-877-423-9813International: 1-201-689-8573Conference ID: 13727899 Webcast:Webcast Link- Click Here The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusi
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
Oppenheimer initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $26.00
Cantor Fitzgerald initiated coverage of Vera Therapeutics with a rating of Overweight
Raymond James initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $29.00
Jefferies upgraded Vera Therapeutics from Hold to Buy and set a new price target of $26.00 from $18.00 previously
Guggenheim initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $27.00
Jefferies downgraded Vera Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously
Wedbush downgraded Vera Therapeutics from Outperform to Neutral and set a new price target of $8.00 from $33.00 previously
JP Morgan initiated coverage of Vera Therapeutics with a rating of Overweight and set a new price target of $35.00
H.C. Wainwright initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $35.00
Wedbush initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $32.00
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veterans to help lead the development of the company's drug programs including its late-stage product candidate, atacicept, to treat autoimmune diseases, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.; and William D. Turner as Chief Development Officer, effective immediately. "We
BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced the appointment of Kerry Cooper, M.D., to the role of Senior Vice President, Medical Affairs, where he will report to Chief Medical Officer Celia Lin and be responsible for overseeing medical affairs strategy and scientific communications. Dr. Cooper brings nearly 40 years of experience in nephrology across a variety of senior positions within industry, clinical practice and academia. He has led medical affairs strategies for drug de
Seasoned Commercial Operations Executive Positions Company for Next Stage of Growth Innocoll Holdings Ltd. ("IHL"), a global biotech pharmaceutical company and portfolio business of Gurnet Point Capital ("GPC"), today announced the appointment of Kimball Hall, a seasoned commercial operations executive, as President and Chief Executive Officer. As part of this appointment, Kimball will also serve as Chief Executive Officer of IHL's two subsidiaries: Syntacoll GmbH ("Syntacoll"), a contract development and manufacturing organization ("CDMO") specializing in collagen-based technology platforms, and Innocoll Biotherapeutics Inc. ("Innocoll"), a global biotech company focusing on delivering no
BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, announced today the appointment Michael M. Morrissey, Ph.D., as chairman of its board of directors. Dr. Morrissey has served as president and chief executive officer (CEO) of Exelixis, Inc. since July 2010. "Mike's experience leading Exelixis' evolution into a fully integrated biopharmaceutical company will be immensely helpful to Vera as we prepare to move from late-stage clinical programs to potential commercial growth," said Kurt von Emster, Vera's cur
BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Kimball Hall to its board of directors. Ms. Hall is a seasoned executive and a chemistry, manufacturing, and controls (CMC) expert. Formerly holding leadership positions at Genentech and Amgen, she is currently president and chief operating officer of Abzena, a biopharmaceutical focused contract development and manufacturing organization (CDMO). "We're honored to welcome Kimball to our board of directors," sai
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Sean Grant, MBA as Chief Financial Officer. In this role, he will oversee all of Vera Therapeutics' financial operations including financial strategy, investor relations, accounting operations, financial planning and analysis, tax, and treasury. Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, commented, "We are fortunate to have an executive with Sean's financial acumen and pedigree join
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be acquired by Waste Management Inc. (NYSE:WM) for approximately $7.2 billion, including debt. Stericycle shares climbed 15% to $59.28 on Monday. Here are some other big stocks recording gains in today’s session. GameStop Corp. (NYSE:GME) shares jumped 34.5% to $31.13 after Roaring Kitty on a Reddit post, shared his position on the stock. MarineMax, Inc. (NYSE:HZO) jumped 27% to $36.16. OneWater Marine Inc. is reportedly said to be in advanced discussions to acquire MarineMax. L
The U.S. stock market ended a five-week positive streak as investors feared that slowing economic momentum could impact the earnings outlook for American corporations. The U.S. economy grew at an annualized rate of 1.3% in the first quarter, marking a downward revision from the previous estimate of 1.6%. The Fed's preferred inflation measure remained steady in April, easing some worries about resuming price pressures. Yet, slowing spending and income growth also signaled weakening consumer health, while the Chicago business activity gauge plummeted to its lowest level since May 2020, raising concerns about a potential end-cycle slowdown. The tech sector, as tracked by the Technology
JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $60 to $65.
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. The chipmaker giant has seen an astounding 186% surge since the end of May 2023, fueled by skyrocketing demand for chips in artificial intelligence development. Veteran Wall Street investor Ed Yardeni recently coined “Magnificent One” to differentiate Nvidia’s extraordinary performance from the Magnificent Seven. To illustrate the magnitude of Nvidia's market value increase, just a year ago, the company was valued at $1 trillion. Today, it boasts a staggering $2.8 trillion valuation, making it the third-largest company in the U.S. Nvidia’s curren
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo;
Raymond James analyst Steven Seedhouse maintains Vera Therapeutics (NASDAQ:VERA) with a Strong Buy and raises the price target from $57 to $68.
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(0.56) per share. This is a 30 percent increase over losses of $(0.80) per share from the same period last year.